Norelgestromin And Ethinyl Estradiol Patch
Product Images NDC 70710-1190

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Norelgestromin And Ethinyl Estradiol (NDC 70710-1190). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2.3 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 01)

Instructional images showing the application sites for the norelgestromin and ethinyl estradiol transdermal patch on the body. The four panels depict a patch applied to the upper arm, lower abdomen, hip, and upper back of a person.*

FDA Label Image

Figure2 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 02)

A horizontal bar chart displaying the number of women with blood clots per 10,000 woman-years across four groups: Non-CHC users (range 1 to 5), CHC users (range 3 to 12), pregnant women (range 5 to 20), and postpartum women within 12 weeks (range 40 to 65). The x-axis represents the number of women with blood clots, with bars proportionate to these ranges.*

FDA Label Image

Figure-2 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 03)

A forest plot chart displaying effect estimates (Odds Ratio/Relative Risk) with 95% confidence intervals for various women's health cohort studies from 2002 to 2017. The x-axis ranges from -1.5 to 2, with data points mostly clustered around 1.0 indicating effect measures from multiple studies on women's contraceptive or hormone use.*

FDA Label Image

Structure (Bf1e449e 61d5 4038 B03c 8b9d576060c0 04)

Chemical structure diagrams of norelgestromin and ethinyl estradiol, the active ingredients in the transdermal patch norelgestromin and ethinyl estradiol by Zydus Pharmaceuticals USA Inc. The structures show the molecular framework and functional groups of each compound.*

FDA Label Image

Figure3 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 05)

A line graph depicting norelgestromin (NGMN) concentration in ng/mL over time in hours for different cycles and weeks of transdermal patch use. The graph shows concentration changes from 0 to 240 hours comparing Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3 with different marker styles for each data set.*

FDA Label Image

Figure4 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 06)

A line graph showing ethinyl estradiol (EE) concentration in pg/mL over time in hours, comparing four different time points during treatment cycles: Cycle 1 Week 1, Cycle 3 Week 1, Cycle 3 Week 2, and Cycle 3 Week 3. The graph tracks changes in EE concentration from 0 to 240 hours, illustrating fluctuations and a notable decline after 168 hours for Cycle 3 Week 3.*

FDA Label Image

Figure5 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 07)

A pharmacokinetic graph showing NGMN (Norelgestromin) concentration in ng/mL over time in hours. It compares the Norelgestromin and Ethinyl Estradiol transdermal system applied to the buttock versus an oral contraceptive containing NGM 250 µg and EE 35 µg. The graph includes data points and trends for both delivery methods over a 240-hour period.*

FDA Label Image

Figure6 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 08)

A line graph depicting the concentration of ethinyl estradiol (EE) in pg/mL over time in hours (h) for different contraceptive methods. It compares the norelgestromin and ethinyl estradiol transdermal system applied to the buttock with an oral contraceptive containing 250 µg norelgestromin and 35 µg ethinyl estradiol. Additionally, it shows estimated steady state data for the oral contraceptive based on day 21. The x-axis represents time in hours from 0 to 240, and the y-axis shows EE concentration from 0 to 130 pg/mL.*

FDA Label Image

Ifu-1 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 09)

Illustration showing a person wearing gloves peeling a norelgestromin and ethinyl estradiol transdermal patch from its protective backing. The image highlights the patch being handled carefully as part of the application process.*

FDA Label Image

Ifu-2 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 10)

An illustration showing a hand holding a small, square transdermal patch, likely representing the norelgestromin and ethinyl estradiol contraceptive patch. The image emphasizes the patch size and how it is held for application.*

FDA Label Image

Ifu-3 (Bf1e449e 61d5 4038 B03c 8b9d576060c0 11)

Instructional illustrations showing application sites for a transdermal patch containing norelgestromin and ethinyl estradiol. The images depict the patch applied to the upper arm, lower abdomen, upper back near the shoulder blade, and upper back near the spine on a female figure.*

FDA Label Image

Carton (Bf1e449e 61d5 4038 B03c 8b9d576060c0 12)

Packaging label for Norelgestromin and Ethinyl Estradiol Transdermal System patch, labeled as 150/35 mcg per day. The label indicates the product is intended for transdermal use only and contains 3 patches per package. The labeler is Zydus Pharmaceuticals USA Inc. The label includes a dosage and storage information panel, barcode, and regulatory statements.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 2)

A clear protective pouch held in a gloved hand, containing a norelgestromin and ethinyl estradiol transdermal patch. The pouch is square and transparent, showing the rectangular medication patch inside. No printed text or labeling is visible on the pouch in the image.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 3)

An instructional illustration showing two hands peeling a protective backing off a transdermal patch. The image demonstrates the step of preparing the patch for application on the skin.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 4)

An instructional illustration showing a person applying a rectangular transdermal patch onto the skin just below the navel on the abdomen. The image demonstrates the placement and application technique of a norelgestromin and ethinyl estradiol contraceptive patch.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 232 5)

An illustration showing a person applying a rectangular transdermal patch to the lower abdominal skin. The patch is white and has rounded corners. The image demonstrates the correct placement of the patch on the body.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 244 2)

A vertical arrow chart illustrating pregnancy rates per 100 women in one year, from fewer than 1 pregnancy at the top to 85 or more pregnancies at the bottom. It categorizes birth control methods by effectiveness, listing implants, injections, intrauterine devices, and sterilization as most effective; followed by birth control pills, skin patch, and vaginal rings; then condoms and diaphragm; next no sex during fertile days, spermicide, and withdrawal; and finally no birth control as resulting in the most pregnancies.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 244 3)

A weekly calendar diagram for a transdermal patch schedule, showing Day 1, Day 8, Day 15 with arrows indicating patch application from Sunday through Saturday in weeks 1, 2, and 3, followed by a Week 4 with no patch applied, labeled as 'NO PATCH' across the days.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 244 4)

A horizontal bar chart showing the number of women with a blood clot per 10,000 woman-years across four groups: Non-CHC user, non-pregnant (range 1 to 5); CHC user (range 3 to 12); pregnancy (range 5 to 20); and postpartum (12 weeks only) with the highest range from 40 to 65. The chart includes notes explaining CHC as combination hormonal contraception and pregnancy data based on a nine-month duration model.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 2)

The image shows a transdermal patch for norelgestromin and ethinyl estradiol, human prescription drug by Zydus Pharmaceuticals USA Inc. The patch is sealed within a clear, square, foil-lined pouch held by a gloved hand. No specific strength or detailed labeling is visible on the patch or packaging.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 3)

An instructional illustration showing hands applying a norelgestromin and ethinyl estradiol transdermal patch to the skin. The image demonstrates proper handling and placement of the contraceptive patch.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 4)

An instructional black-and-white image showing the application of a transdermal patch on the lower abdomen. A person's hands are applying a square patch to the skin, demonstrating proper placement and adhesion technique.*

FDA Label Image

Image (Bf1e449e 61d5 4038 B03c 8b9d576060c0 52 5)

An illustration showing hands applying a norelgestromin and ethinyl estradiol transdermal patch to the lower abdomen. The patch is rectangular and visibly centered on the skin, demonstrating correct placement for this hormonal contraceptive method.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.